A global comparison of hepatitis B & C drug pricing
HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities.
Authors
- Catherine Tsai (ORCID: https://orcid.org/0000-0002-5675-1941)
- Xiaohan Ying (ORCID: https://orcid.org/0000-0001-5586-4314)
- Arun Jesudian (ORCID: https://orcid.org/0000-0002-8562-3375)
- Stephen E. Congly (ORCID: https://orcid.org/0000-0002-3342-3531)
- Leah Yao
- Gunjan Malik (ORCID: https://orcid.org/0009-0003-6705-5858)
- Robert S. Brown (ORCID: https://orcid.org/0000-0002-8220-065X)
Institutions
- NewYork–Presbyterian Hospital (US)
- University of Calgary (CA)
- Cornell University (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- Annals of Hepatology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1016/j.aohep.2025.101928
- Citations
- 2
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71